GlassScriptPhysician profile
Kartik Anand
NPI 1164863841
$24,118.39
in general payments reported to CMS, 2019-2025
39 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $173 · 2021: $1,555 · 2022: $448 · 2023: $587 · 2024: $7,060 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,475 · Consulting Fee: $7,335 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Travel and Lodging: $1,589 · Food and Beverage: $1,436 · Honoraria: $200 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,475.00 |
| Consulting Fee | $7,335.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Travel and Lodging | $1,588.99 |
| Food and Beverage | $1,436.46 |
| Honoraria | $200.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $9,359.92 | 2022-2025 | Optune Lua (Novottf-200t) |
| Gilead Sciences, INC. | $4,414.27 | 2025 | Trodelvy |
| Abbvie INC. | $3,651.26 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,410.48 | 2024-2025 | |
| Pfizer INC. | $1,519.87 | 2021-2024 | |
| Seagen INC. | $279.92 | 2019-2023 | Tukysa |
| Daiichi Sankyo INC. | $200.00 | 2023 | |
| Medtronic Vascular, INC. | $150.50 | 2020 | |
| Boston Scientific Corporation | $140.06 | 2023 | Watchman Flx |
| Adc Therapeutics America, INC. | $125.00 | 2023 | |
| Lilly USA, LLC | $93.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $83.98 | 2022-2024 | Imbruvica, Tecvayli, Talvey |
| Abbott Laboratories | $51.96 | 2023-2024 | Jot Dx, Cardiomems |
| Celgene Corporation | $49.08 | 2019-2025 | Reblozyl |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $42.01 | 2025 | Xt Cdx |
| Eisai INC. | $37.63 | 2024-2025 | |
| Tersera Therapeutics LLC | $36.84 | 2023 | Xermelo |
| Incyte Corporation | $36.10 | 2019-2021 | |
| Genzyme Corporation | $33.93 | 2022-2025 | |
| Janssen Biotech, INC. | $29.96 | 2019-2021 | |
| Kite Pharma, INC. | $25.39 | 2023 | |
| Pharmaessentia USA Corporation | $23.68 | 2025 | Besremi |
| Servier Pharmaceuticals LLC | $21.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.02 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $19.28 | 2022 | |
| Novo Nordisk INC | $17.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.54 | 2022 | |
| Heron Therapeutics, INC. | $16.12 | 2022 | |
| Rigel Pharmaceuticals, INC. | $16.06 | 2019 | |
| Genentech USA, INC. | $15.45 | 2025 | Itovebi |
| Amgen INC. | $14.42 | 2023 | Lumakras |
| Cti Biopharma Corp. | $12.78 | 2023 | Vonjo |
| Merck Sharp & Dohme LLC | $12.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.88 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.85 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kartik Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.